Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2003
06/26/2003US20030119829 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of PDE7B-mediated diseases and conditions
06/26/2003US20030119827 Peptidyl carbamates; treatments for osteoporosis and autoimmune diseases
06/26/2003US20030119826 Neuroprotective treatment methods using selective iNOS inhibitors
06/26/2003US20030119823 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydrox y-1,6-naphthyridine-7-carboxamide; preventing or treating hiv or aids
06/26/2003US20030119820 Substituted indoles
06/26/2003US20030119819 Anticancer agents
06/26/2003US20030119818 CRF antagonistic quino-and quinazolines
06/26/2003US20030119803 In particular N-epsilon-amino acid substituted L-lysine derivatives possessing aspartyl protease inhibitory properties.
06/26/2003US20030119802 Use particularly in the prophylaxis and treatment of respiratory diseases.
06/26/2003US20030119797 Methods for selective immunomodulation
06/26/2003US20030119793 CAK inhibitors and uses thereof
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119787 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B
06/26/2003US20030119786 Combinations for the treatment of immunoinflammatory disorders
06/26/2003US20030119780 Therapeutical treatments
06/26/2003US20030119778 Novel gene useful for diagnosis and treatment of aplasia of corpus callosum and aspermatogenesis and use thereof
06/26/2003US20030119777 Oligoribonucleotides and ribonucleases for cleaving RNA
06/26/2003US20030119769 Antisense oligonucleotide modulation of raf gene expression
06/26/2003US20030119753 Novel ascorbic acid compounds, methods of synthesis and application use thereof
06/26/2003US20030119752 Inhibiting particularly the activity of hepatitis C virus NS3-NS4A protease; peptidomimetics having a bridged bicyclic moiety at the P2 position.
06/26/2003US20030119749 Novel compounds possessing antibacterial, antifungal or antitumor activity
06/26/2003US20030119748 Use for treatment of inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury.
06/26/2003US20030119746 Treatment of both primary and metastatic solid tumors
06/26/2003US20030119744 Treatment with Prostate Secretory Protein-94 led to a near normalization of plasma calcium and a marked reduction in PTHrP production
06/26/2003US20030119742 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
06/26/2003US20030119729 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease
06/26/2003US20030119727 FVIIa antagonists
06/26/2003US20030119726 P-glycoproteins and uses thereof
06/26/2003US20030119718 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119188 Novel compounds
06/26/2003US20030119168 Diagnosis of anticancer agents using nucleic acids
06/26/2003US20030119158 Polynucleotide compositions encoding broad-spectrum delta endotoxins
06/26/2003US20030119148 Amino-terminally truncated rantes as chemokine antagonists
06/26/2003US20030119088 Phosphorylation of proteins; therapy for lysosome storage disease
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030119072 Methods for modulating signal transduction mediated by TGF-beta related proteins
06/26/2003US20030119045 Controlling cell proliferation; adjust adhesion to substrate
06/26/2003US20030118677 Method of isolating extract from the euphorbaciae obesa plant and methods for using the same
06/26/2003US20030118672 Administering a stabilized rice bran derivative and a fortification agent; treating bone disorders
06/26/2003US20030118657 Treatment of disease states characterized by excessive or inappropriate angiogenesis
06/26/2003US20030118644 A solid forms comprising low molecular weight peptide-based thrombin inhibitor having pH dependent solubility, cellulose or starch as disintegrant fillers; immediate release
06/26/2003US20030118640 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate
06/26/2003US20030118633 Treating unstable or overactive urinary bladder by administering an antimuscarinic agent and an estrogen agonist
06/26/2003US20030118606 Contains mycelium fraction of a product obtained by incubation of mycelia of Ganoderma boninense and induces production of interleukin 12; use as terminal cancer treatment or supplementary food preparation
06/26/2003US20030118582 Pharmaceutical composition comprising factor VII polypeptides and protein C inhibitors
06/26/2003US20030118575 Administering a pyrazole compound containing urea or thiourea groups, twice daily to a patient in need of treatment of a cytokine mediated disease
06/26/2003US20030118559 Contacting the bodily fluid of a patient with renal tubule cells outside of the kidney for treating systemic inflammatory response syndrome (SIRS)
06/26/2003US20030118536 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003US20030118528 Topical delivery of codrugs
06/26/2003US20030118513 Lung administering; bioavailability
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003CA2473938A1 Human adam-10 inhibitors
06/26/2003CA2471777A1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2470811A1 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003CA2470723A1 3,4-dihydro-1h-isoquinolin-2-yl-derivatives
06/26/2003CA2470640A1 Use of hmgb proteins and nucleic acids that code therefor
06/26/2003CA2470624A1 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
06/26/2003CA2470616A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003CA2470567A1 Methods and compositions for treatment of central nervous system disorders
06/26/2003CA2470491A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2470419A1 Growth factor modified protein matrices for tissue engineering
06/26/2003CA2470315A1 Methods of detecting modification of genetic material
06/26/2003CA2470307A1 Protein kinase inhibitors
06/26/2003CA2470236A1 Lactams as tachykinin antagonists
06/26/2003CA2470214A1 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
06/26/2003CA2470060A1 Improvements in pharmaceutical compositions
06/26/2003CA2469984A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003CA2469976A1 Improvements in pharmaceutical compositions
06/26/2003CA2469790A1 Method for treating circadian rhythm disruptions
06/26/2003CA2469786A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003CA2469302A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003CA2469048A1 Quinolinones as prostaglandin receptor ligands
06/26/2003CA2468880A1 Tetrahydrocarbazole derivatives as ligands for g-protein coupled receptors (gpcr)
06/26/2003CA2468783A1 Cis-imidazolines as mdm2 inhibitors
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2467780A1 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
06/26/2003CA2467279A1 Solubilized topoisomerase poison agents
06/26/2003CA2465888A1 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003CA2460806A1 Taojiks as modifiers of the beta-catenin pathway and methods of use
06/26/2003CA2453417A1 Nanoparticle delivery vehicle
06/25/2003EP1321475A1 Gene useful for diagnosis and treatment of aplasia of corpus callosum and aspermatogensis and use thereof
06/25/2003EP1321461A1 N-(Cyclopropylmethyl)-azacycloalkanes, compositions containing them and methods for their preparation
06/25/2003EP1321434A1 Method and apparatus for preparing aqueous dispersion of ultra-fine active carbon particles
06/25/2003EP1321151A1 Antiparkinsonism drugs
06/25/2003EP1321143A1 Combination of N-butyldeoxygalactonojirimycin and glycolipid degrading enzyme in therapy
06/25/2003EP1321142A1 Solid pharmaceutical composition for oral administration of Tegaserod
06/25/2003EP1320614A2 Novel proteases
06/25/2003EP1320613A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/25/2003EP1320603A1 Uses of the gjb6 gene for treating certain types of alopecia including the clouston's syndrome, and for screening compounds capable of being efficient in the treatment of alopecia with genetic susceptibility
06/25/2003EP1320600A1 Transporters and ion channels
06/25/2003EP1320585A2 Oxidoreductases
06/25/2003EP1320584A2 Transferases
06/25/2003EP1320552A1 Method for producing human anti-thymocyte immunoglobulins
06/25/2003EP1320551A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma
06/25/2003EP1320550A2 G-protein coupled receptors
06/25/2003EP1320549A2 Pumpcn compositions and uses thereof
06/25/2003EP1320546A2 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
06/25/2003EP1320541A2 Tgf-beta inhibitors and methods
1 ... 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 ... 1564